Clinical and Biological Implications of Tumor Heterogeneity (2023)

Linthicum, MD US
March 3, 2023 to March 4, 2023

Johns Hopkins Greenberg Bladder Cancer Institute and American Urological Association Translational Research Collaboration

Clinical and Biological Implications of Tumor Heterogeneity (2023) will be held in-person, March 3-4, 2023 at AUA Headquarters in Linthicum, MD.

The sixth annual translational research meeting co-sponsored by the American Urological Association and the Johns Hopkins Greenberg Bladder Cancer Institute will be a two-day, in-person symposium focused on the “Clinical and Biological implications of Tumor Heterogeneity”.

Large genomics projects such as The Cancer Genome Atlas (TCGA) and UROMOL bladder cancer projects provided “snapshot” descriptions of bladder cancer based on bulk tumor sequencing data.  New single-cell and spatial profiling platforms and longitudinal measurements of primary tumors, recurrences, and metastases are revealing tumor heterogeneity that presents challenges for biomarker development and precision medicine.  The purpose of this workshop is to bring together clinical and research thought leaders to review the current state of the science and develop new methods for accommodating tumor heterogeneity in biomarker development and the clinical management of bladder cancer in patients.  The workshop will focus on 4 major research areas that appear to be significantly impacted by tumor heterogeneity – molecular subtypes, DNA-based clonal evolution, the tumor immune landscape, and bladder cancer histologic variants.

Note the deadline for registration is Thursday, March 2, 2023 at 12:OO pm EST. 

PROGRAM PLANNING COMMITTEE

  • David McConkey, PhD (Chair) - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Aria, Olumi, MD - Beth Israel Deaconess and Harvard Medical School
  • Diane Zipursky Quale, JD - Bladder Cancer Advocacy Network
  • Andrea Apolo, MD - National Cancer Institute
  • Arlene Siefker-Radtke, MD - University of Texas MD Anderson Cancer Center
  • Rosalyn Adam, PhD - Boston Children's Hospital
  • Philip Beachy, PhD - Stanford Medicine
  • Jason Efstathiou, MD, DPhil - Harvard Medical School, Massachusetts General Hospital
  • Phuoc Tran, MD, PhD - Johns Hopkins 
  • Peter Black, MD - Vancouver Prostate Centre, University of British Columbia
  • Yair Lotan, MD - UT Southwestern Medical Center
  • Seth Lerner, MD - Baylor College of Medicine
  • Joshua Meeks, MD, PhD - Northwestern Medicine
  • James McKierman, MD - Columbia University
  • Eugene Pietzak, MD -  Memorial Sloan Kettering Cancer Center
  • Rick Bangs, MBA - SWOG Cancer Research Network

COURSE REGISTRATION FEES

Membership CategoryPrice

MD/PhD Member

$235

MD/PhD Non-Member

$290

Member Medical Student, Resident, Fellow

$160

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$475

Invited Faculty/Speakers

$0

 

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

  • Merck & Co., Inc
  • AstraZeneca

 

Target Audience

  • Urologists
  • Research scientists
  • Clinical and research faculty
  • Clinical and postdoctoral fellows
  • Residents
  • Medical and graduate students
  • Medical professionals employed by industry

Learning Objectives

At the conclusion of this meeting, participants will be able to:

  1. Describe the extent to which tumor heterogeneity influences the major RNA- and DNA-based biomarkers that are being developed for bladder preservation, selection of adjuvant therapy, and other personalized clinical management approaches.
  2.  Discuss the biological basis for tumor heterogeneity and gaps in current knowledge about these mechanisms.
  3.  Explain patient perspectives on the use of biomarkers for guiding clinical management of bladder cancer.
  4.   Describe strategies to overcome the challenges presented by tumor heterogeneity.
Course summary
Available credit: 
  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Non-Physician Participation
Course opens: 
01/01/2023
Course expires: 
03/04/2026
Event starts: 
03/03/2023 - 2:30pm EST
Event ends: 
03/04/2023 - 2:50pm EST
Price:
$235.00
Rating: 
0

*agenda updates will be posted as they become available.
All times are listed in EST.

2023 AUA-JHU GBCI Bladder Cancer Research Symposium
Clinical and Biological implications of tumor Heterogeneity

Friday, March 3 - Saturday, March 4, 2023

AUA Headquarters, Linthicum, Maryland, USA

FRIDAY, March 3, 2023

Time

Running Time

Title

Speaker

2:00 PM

30 min

Arrival, Registration, Coffee and Refreshments

n/a

2:30 PM

30 min

Welcome, Opening Remarks, and Goal Setting

David McConkey, PhD

Director, Johns Hopkins Greenberg Bladder Cancer Institute

Welcome Address

Dr. Christine Riordan, AUA Office of Research Director

3:00 PM

1 hour

Patient Perspectives Panel: Patient Perspectives and why they matter to research
Moderator: Stephanie Chisolm, PhD
Moderator: Pamela Goetz

Moderator: Stephanie Chisolm, PhD

Moderator: Pamela Goetz

Patient: Karen Sachse

Patient: Susan Bell

Patient: George Purring

Patient: Mike Strich

4:00 PM

15 min

Discussion, Q&A

 

4:15 PM

15 min

Break

 

4:30 PM

1 hr

 30 min

SESSION 1: Molecular heterogeneity and plasticity in the molecular subtypes of bladder cancer                                        
Moderator: Eugene Pietzak

                                              

Seth Lerner, Baylor
SUBTYP: a molecular subtypes-based neoadjuvant trial
Woonyoung Choi, JHU
Molecular subtypes and response to chemotherapy
Clarice Groeneveld, Institut Curie
BoBCaT: Molecular subtypes and response to chemotherapy: the VESPER trial
Michael Shen, Columbia
Chromatin-modifying enzymes and subtype plasticity
Joshua Warrick, Penn State
Molecular subtypes: pathology considerations

6:00 PM

15 min

Discussion Q/A

 

6:15 PM

 

Networking Reception and Dinner

 

8:30 PM

 

Adjourn

Johns Hopkins and AUA staff will escort attendees to reception location

Saturday, March 4, 2023

Time

Running Time

Title

Speaker Name

8:00 AM

30 min

Breakfast and Morning Registration

 

8:30 AM

1hr 30 min

SESSION 2: Clonal Evolution
Moderator: Hikmat Al-Ahmadie

Bishoy Faltas, Weill Cornell
Extrachromosomal DNA reflects the footprint of mutagenic processes and drives oncogene amplification in urothelial carcinoma
Andrew Hsieh FHCRC
mRNA translation and clonal evolution in bladder cancer
Lars Dyrskjot, Aarhus
Circulating tumor DNA and clonal evolution
Gillian Vandekerkhove, UBC
ctDNA to assess genomic heterogeneity
Roger Li, Moffitt Cancer Center
Urine tumor DNA and clonal evolution
Eugene Pietzak , MSKCC
Clinical implications of tumor evolution in (Localized) urothelial carcinoma

10:00 AM

15 min

Discussion Q/A

 

10:15 AM

15 min

Break

 

10:30 AM

1hr 15 min

SESSION 3: Heterogeneity in the tumor immune landscape
Moderator: David McConkey

Andrea Apolo, NCI
Heterogeneity in the responses to systemic immunotherapy
Elisabeth De Vries, University Medical Centre Groningen
Whole body imaging of tumor immune heterogeneity
William Kim, UNC

The path to predicting ICI response: a long or never-ending road?
David Degraff, Penn State                                                                      Lineage plasticity and urothelial intrinsic inflammatory signaling
Amir Horowitz, Mt Sinai

Dually targeting NK/CD8 T cells for the treatment of BCG-unresponsive NMIBC

11:45 AM

15 min

Discussion Q/A

 

12:00 PM15 minLunch is served 

12:15 PM

45 min

Lunch Keynote

David Solit, MSKCC
Defining the Actionable Genome

1:00 PM

1hr

SESSION 4: Variant histology: Origin and Implications
Moderator: David Degraff

 

Donna Hansel, MD Anderson
Clinical significance of variants and mixed tumors
Jonathan Rosenberg, MSKCC
Variant histology urothelial cancers and response to systemic therapies
Hikmat Al-Ahmadie, MSKCC
New insights into urothelial carcinoma with squamous differentiation
Andres Matoso, JHU
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder

2:00 PM

15 min

Discussion

 

2:15 PM

15 min

Meeting Summary and Action Items

 

2:30 PM

 

Closing Remarks / Adjourn

 

 

AUA Headquarters
1000 Corporate Boulevard
Linthicum, MD 21090
United States

Clinical and Biological Implications of Tumor Heterogeneity (2023) will be held in-person on March 3-4, 2023 at the AUA Headquarters. 


Hotel Information

The AUA has reserved a block of rooms at the Hilton Garden Inn BWI Airport, 1516 Aero Drive, Linthicum Heights, MD 21090.

  • To hold a reservation, a major credit card number must be provided.
  • The room block is for Friday, March 3, 2023 only. (If you require additional nights, please contact Shira Rubin at srubin@auanet.org to assist you.)
  • $104 single/double occupancy.

Make your reservation online or call 410-691-0500 and reference the AUA/JHU Bladder Cancer Meeting when making your reservation to receive the special group rate.

Click Here to Reserve Your Room

Cut-off Date: Friday, February 17, 2023. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Check-in: 3pm
Check-out: 12pm
 

Travel

Please contact Shira Rubin, srubin@auanet.org for hotel and travel information.

COI Work Group Disclosures

PDF icon COI Review Work Group Disclosures_2023_062822.pdf

Faculty and Planner Disclosures 

NameCompany NameRelationship TypeEnd Date
Adam, Rosalyn M.None  
Al-Ahmadie, HikmatNone  
Apolo, AndreaNone  
Bangs, RickNonagenConsultant or AdvisorCurrent
Beachy, PhilipCuris incInvestment InterestCurrent
Beachy, PhilipFate TherapeuticsInvestment InterestCurrent
Bell, SusanNone  
Black, Peter ColinAbbVieConsultant or AdvisorCurrent
Black, Peter ColinAstellasConsultant or AdvisorCurrent
Black, Peter ColinAstraZenecaConsultant or AdvisorCurrent
Black, Peter ColinBayerConsultant or AdvisorCurrent
Black, Peter ColinBiosyentMeeting Participant or Lecturer09/01/2022
Black, Peter ColinBristol Myers SquibbConsultant or AdvisorCurrent
Black, Peter ColinEMD SeronoConsultant or AdvisorCurrent
Black, Peter ColinFerringConsultant or AdvisorCurrent
Black, Peter ColinJanssenConsultant or AdvisorCurrent
Black, Peter ColinMerckConsultant or AdvisorCurrent
Black, Peter ColinMinogueMeeting Participant or Lecturer09/01/2022
Black, Peter ColinmiR ScientificConsultant or AdvisorCurrent
Black, Peter ColinNanOlogyConsultant or AdvisorCurrent
Black, Peter ColinNonagenConsultant or AdvisorCurrent
Black, Peter ColinPacific EdgeScientific Study or TrialCurrent
Black, Peter ColinPfizerMeeting Participant or LecturerCurrent
Black, Peter ColinProkariumConsultant or AdvisorCurrent
Black, Peter ColinProtaraConsultant or AdvisorCurrent
Black, Peter ColinQED BiosciencesConsultant or Advisor04/01/2021
Black, Peter ColinRoche/GenentechConsultant or AdvisorCurrent
Black, Peter ColinSanofiConsultant or AdvisorCurrent
Black, Peter ColinSesen BioConsultant or AdvisorCurrent
Black, Peter ColinSTIMITConsultant or Advisor08/31/2021
Black, Peter ColinTolmarConsultant or AdvisorCurrent
Black, Peter ColinUroGenConsultant or AdvisorCurrent
Black, Peter ColinVerity PharmaceuticalsConsultant or AdvisorCurrent
Chisolm, StephanieNone  
Choi, WoonyoungNone  
De Vries, ElisabethAmgenScientific Study or TrialCurrent
De Vries, ElisabethAstraZenecaScientific Study or TrialCurrent
De Vries, ElisabethBayerScientific Study or Trial12/01/2021
De Vries, ElisabethCrescendo BiologicsConsultant or AdvisorCurrent
De Vries, ElisabethCrescendo BiologicsScientific Study or TrialCurrent
De Vries, ElisabethCytomXScientific Study or TrialCurrent
De Vries, ElisabethDaiichi SankyoConsultant or AdvisorCurrent
De Vries, ElisabethG1 TherapeuticsScientific Study or TrialCurrent
De Vries, ElisabethGE HealthcareScientific Study or TrialCurrent
De Vries, ElisabethGenentechScientific Study or TrialCurrent
De Vries, ElisabethRegeneronScientific Study or TrialCurrent
De Vries, ElisabethRocheScientific Study or TrialCurrent
De Vries, ElisabethServierScientific Study or TrialCurrent
De Vries, ElisabethSynthonScientific Study or TrialCurrent
DeGraff, DavidBristol Myers SquibbScientific Study or Trial11/01/2023
Dos Santos Groeneveld, ClariceNone  
Dyrskjot, LarsAstraZenecaScientific Study or TrialCurrent
Dyrskjot, LarsFerringScientific Study or TrialCurrent
Dyrskjot, LarsFerringConsultant or AdvisorCurrent
Dyrskjot, LarsNateraScientific Study or TrialCurrent
Dyrskjot, LarsPhotocureScientific Study or TrialCurrent
Dyrskjot, LarsUroGenConsultant or AdvisorCurrent
Efstathiou, JasonAstraZeneca PharmaceuticalsConsultant or AdvisorCurrent
Efstathiou, JasonBayerConsultant or Advisor01/27/2022
Efstathiou, JasonBlue Earth DiagnosticsConsultant or Advisor12/07/2022
Efstathiou, JasonBlueEarth DiagnosticsConsultant or AdvisorCurrent
Efstathiou, JasonBoston ScientificConsultant or AdvisorCurrent
Efstathiou, JasonGenentechConsultant or Advisor02/16/2022
Efstathiou, JasonGileadConsultant or Advisor09/09/2022
Efstathiou, JasonJanssenConsultant or Advisor11/26/2021
Efstathiou, JasonLantheusConsultant or Advisor11/19/2022
Efstathiou, JasonMyovantConsultant or Advisor10/24/2022
Efstathiou, JasonPfizerConsultant or Advisor06/23/2022
Efstathiou, JasonProgenics PharmaceuticalsConsultant or Advisor05/15/2022
Faltas, BishoyAstrin biosciencesConsultant or AdvisorCurrent
Faltas, BishoyBoston GeneConsultant or AdvisorCurrent
Faltas, BishoyEli LillyScientific Study or TrialCurrent
Faltas, BishoyGuardantConsultant or AdvisorCurrent
Faltas, BishoyJanssenConsultant or AdvisorCurrent
Faltas, BishoyMerckConsultant or AdvisorCurrent
Faltas, BishoyNateraConsultant or AdvisorCurrent
Faltas, BishoyQED TherapueticsConsultant or AdvisorCurrent
Faltas, BishoySeattle GeneticsConsultant or AdvisorCurrent
Goetz, PamelaNone  
Hansel, Donna E.AstraZenecaConsultant or AdvisorCurrent
HOROWITZ, AMIRImmunorizonConsultant or AdvisorCurrent
HOROWITZ, AMIRTakedaConsultant or Advisor06/05/2022
HOROWITZ, AMIRUroGenConsultant or AdvisorCurrent
HOROWITZ, AMIRZumutor BiologicsConsultant or AdvisorCurrent
Hsieh, AndrewPfizerOther-We are using a preclinical compound from Pfizer for a study in mice.Current
Kaplan, Steven AbrahamNone  
Kim, William YAbbvieInvestment InterestCurrent
Kim, William YAmgenInvestment InterestCurrent
Kim, William YArvinas IncInvestment InterestCurrent
Kim, William YBeigeneInvestment InterestCurrent
Kim, William YBriston-Myers SquibbInvestment InterestCurrent
Kim, William YFibrogenInvestment Interest01/01/2023
Kim, William YGeneCentricConsultant or Advisor01/01/2023
Kim, William YGeneCentricOther-Research Funding01/01/2023
Kim, William YH3 BiomedicineOther-Travel, Accommodations01/01/2023
Kim, William YIlluminaInvestment Interest01/01/2023
Kim, William YJohnson and JohnsonInvestment Interest01/01/2023
Kim, William YKura OncologyInvestment Interest01/01/2023
Kim, William YMerckOther-Research FundingCurrent
Kim, William YMyovantInvestment InterestCurrent
Kim, William YNextCureInvestment Interest01/03/2023
Kim, William YOramedInvestment Interest01/01/2023
Kim, William YRentals PharmaceuticalsInvestment InterestCurrent
Kim, William YSpectrumInvestment Interest01/01/2023
Kim, William YTakedaOther-Travel, Accommodations01/01/2023
Lerner, Seth PaulAura BiosciencesScientific Study or TrialCurrent
Lerner, Seth PaulBMSConsultant or AdvisorCurrent
Lerner, Seth PaulC2i GenomicsConsultant or AdvisorCurrent
Lerner, Seth PaulFerGeneConsultant or AdvisorCurrent
Lerner, Seth PaulFKDScientific Study or TrialCurrent
Lerner, Seth PaulIncyteConsultant or Advisor10/29/2023
Lerner, Seth PaulPfizerConsultant or AdvisorCurrent
Lerner, Seth PaulProtaraConsultant or Advisor09/14/2023
Lerner, Seth PaulQED TherapeuticsConsultant or Advisor04/01/2021
Lerner, Seth PaulQED TherapeuticsScientific Study or Trial12/18/2022
Lerner, Seth PaulRoche/GenetechScientific Study or TrialCurrent
Lerner, Seth PaulStimitConsultant or AdvisorCurrent
Lerner, Seth PaulUpToDateHealth PublishingCurrent
Lerner, Seth PaulVaxiionConsultant or AdvisorCurrent
Lerner, Seth PaulVaxiionScientific Study or TrialCurrent
Lerner, Seth PaulVerityConsultant or AdvisorCurrent
Lerner, Seth PaulViventiaScientific Study or TrialCurrent
Li, RogerArquer DiagnosticsConsultant or Advisor01/20/2023
Li, RogerBeam TherapeuticsInvestment InterestCurrent
Li, RogerBMSScientific Study or TrialCurrent
Li, RogerCrispr TherapeuticsInvestment InterestCurrent
Li, RogerDecipherScientific Study or TrialCurrent
Li, RogerEli LillyInvestment Interest10/03/2022
Li, RogerFergeneConsultant or Advisor01/01/2022
Li, RogerGuardant HealthInvestment InterestCurrent
Li, RogerIntellia TherapeuticsInvestment InterestCurrent
Li, RogerPredicineScientific Study or TrialCurrent
Li, RogerUrogen PharmaConsultant or Advisor01/22/2023
Lotan, YairAbbvieConsultant or AdvisorCurrent
Lotan, YairAmbuConsultant or AdvisorCurrent
Lotan, YairAstra zenecaConsultant or AdvisorCurrent
Lotan, YairAura BiosciencesConsultant or AdvisorCurrent
Lotan, YairC2I genomicsConsultant or AdvisorCurrent
Lotan, YairCAPs MedicalConsultant or AdvisorCurrent
Lotan, Yaircg oncologyConsultant or AdvisorCurrent
Lotan, YairCleveland DiagnosticsConsultant or AdvisorCurrent
Lotan, YairConvergent GenomicsConsultant or AdvisorCurrent
Lotan, YairEngeneConsultant or AdvisorCurrent
Lotan, YairFergeneConsultant or AdvisorCurrent
Lotan, YairMDxHealthScientific Study or TrialCurrent
Lotan, YairMerck IncConsultant or AdvisorCurrent
Lotan, YairNonagenConsultant or AdvisorCurrent
Lotan, YairNucleixConsultant or AdvisorCurrent
Lotan, YairPacific EdgeConsultant or AdvisorCurrent
Lotan, YairPfizerConsultant or AdvisorCurrent
Lotan, YairSeattle geneticsConsultant or AdvisorCurrent
Lotan, YairStimitConsultant or AdvisorCurrent
Lotan, YairUrogenOther-chair, Data Monitoring and Safety CommitteeCurrent
Lotan, YairurogenConsultant or AdvisorCurrent
Lotan, YairUrogenOther-chair, Data Monitoring and Safety CommitteeCurrent
Lotan, YairValar labConsultant or AdvisorCurrent
Lotan, YairVerity pharmaceuticalsConsultant or AdvisorCurrent
Lotan, YairVessi MedicalConsultant or AdvisorCurrent
Matoso, AndresNone  
McConkey, DavidJanssenConsultant or Advisor01/03/2022
McKiernan, James MichaelmiR ScientificConsultant or Advisor09/30/2022
Pietzak III, Eugene JonMerck & CoConsultant or AdvisorCurrent
Pietzak III, Eugene JonUrogenConsultant or AdvisorCurrent
Pietzak III, Eugene JonQED TherapeuticsScientific Study or TrialCurrent
Pietzak III, Eugene JonJanssenScientific Study or TrialCurrent
Riordan, ChristineNone  
Rosenberg, Jonathan E.Aadi BioscienceConsultant or Advisor10/17/2023
Rosenberg, Jonathan E.Alligator BiosciencesConsultant or AdvisorCurrent
Rosenberg, Jonathan E.AstellasConsultant or AdvisorCurrent
Rosenberg, Jonathan E.AstellasConsultant or AdvisorCurrent
Rosenberg, Jonathan E.AstraZenecaConsultant or AdvisorCurrent
Rosenberg, Jonathan E.BMSConsultant or Advisor10/16/2021
Rosenberg, Jonathan E.Boehringer IngelheimConsultant or AdvisorCurrent
Rosenberg, Jonathan E.Eli LillyConsultant or Advisor03/31/2022
Rosenberg, Jonathan E.EMD SeronoConsultant or AdvisorCurrent
Rosenberg, Jonathan E.EMD-SeronoMeeting Participant or Lecturer12/08/2021
Rosenberg, Jonathan E.EMD-SeronoMeeting Participant or Lecturer12/08/2021
Rosenberg, Jonathan E.GenentechConsultant or AdvisorCurrent
Rosenberg, Jonathan E.Gilead/ImmunomedicsConsultant or AdvisorCurrent
Rosenberg, Jonathan E.HengruiConsultant or Advisor02/14/2024
Rosenberg, Jonathan E.IMVaxConsultant or Advisor08/10/2024
Rosenberg, Jonathan E.Infinity PharmaceuticalsConsultant or Advisor08/31/2022
Rosenberg, Jonathan E.MedscapeHealth Publishing08/31/2023
Rosenberg, Jonathan E.MerckConsultant or AdvisorCurrent
Rosenberg, Jonathan E.MiratiConsultant or AdvisorCurrent
Rosenberg, Jonathan E.PfizerConsultant or Advisor10/14/2022
Rosenberg, Jonathan E.PfizerMeeting Participant or LecturerCurrent
Rosenberg, Jonathan E.QEDConsultant or Advisor03/26/2024
Rosenberg, Jonathan E.SeagenConsultant or AdvisorCurrent
Rosenberg, Jonathan E.Tyra BiosciencesConsultant or AdvisorCurrent
Shen, Michael M.None  
Siefkerradtke, Arlene OAstrazenecaConsultant or AdvisorCurrent
Siefkerradtke, Arlene OBavarian NordicConsultant or AdvisorCurrent
Siefkerradtke, Arlene OBristol-Myers SquibbScientific Study or TrialCurrent
Siefkerradtke, Arlene OCurioConsultant or AdvisorCurrent
Siefkerradtke, Arlene OG1 TherapeuticsConsultant or AdvisorCurrent
Siefkerradtke, Arlene OGenentechConsultant or AdvisorCurrent
Siefkerradtke, Arlene OIdeayaConsultant or AdvisorCurrent
Siefkerradtke, Arlene OImmunomedicsConsultant or AdvisorCurrent
Siefkerradtke, Arlene OJanssenScientific Study or TrialCurrent
Siefkerradtke, Arlene OLoxo-OncologyConsultant or AdvisorCurrent
Siefkerradtke, Arlene OMerck & CoScientific Study or TrialCurrent
Siefkerradtke, Arlene OMerck Sharp & DohmeConsultant or AdvisorCurrent
Siefkerradtke, Arlene OMillenniumScientific Study or TrialCurrent
Siefkerradtke, Arlene OMiratiConsultant or AdvisorCurrent
Siefkerradtke, Arlene ONateraConsultant or AdvisorCurrent
Siefkerradtke, Arlene ONektarScientific Study or TrialCurrent
Siefkerradtke, Arlene ONektarConsultant or AdvisorCurrent
Siefkerradtke, Arlene OSeagenConsultant or AdvisorCurrent
Siefkerradtke, Arlene OSeattle GeneticsConsultant or AdvisorCurrent
Siefkerradtke, Arlene OTaihoConsultant or AdvisorCurrent
Solit, David B.PfizerConsultant or AdvisorCurrent
Solit, David B.BridgeBioConsultant or AdvisorCurrent
Solit, David B.Rain TherapeuticsOther-Member, Data Safety Monitoring BoardCurrent
Tran, Phuoc T.Janssen-Taris BiomedicalIntellectual PropertyCurrent
Tran, Phuoc T.Natsar PharmIntellectual PropertyCurrent
Vandekerkhove, GillianNone  
Warrick, JoshuaNone  
Zipursky Quale, DianeNone  

AUA Staff have nothing to disclose.

All relevant financial disclosures have been mitigated.

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Non-Physician Participation

Price

Price:
$235.00
Please login or register to take this course.

Note the deadline for registration is Thursday, March 2, 2023 at 12:OO pm EST. 

Registration Fees

Membership CategoryPrice

MD/PhD Member

$235

MD/PhD Non-Member

$290

Member Medical Student, Resident, Fellow

$160

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$475

Invited Faculty/Speakers

$0

Required Hardware/software

Laptop or tablet with Wi-Fi capabilities
Charger